Background: Guidelines caution against the use of non–vitamin K antagonist oral
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …

Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with
vitamin K antagonists (VKAs). Vitamin K antagonist use is limited, in part, by the high …

We investigated stroke outcomes in normal weight (body mass index [BMI] 18.50 to 24.99
kg/m 2), overweight (BMI 25.00 to 29.99 kg/m 2), and obese (BMI≥ 30 kg/m 2) patients with …

Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …

Abstract Background In the ARISTOTLE (Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation) trial, patients with atrial fibrillation and≥ 2 dose …

Importance In the Apixaban for Reduction of Stroke and Other Thromboembolic
Complications in Atrial Fibrillation (ARISTOTLE) trial, the standard dose of apixaban was 5 …

Relatively little is known about the influence of extreme body weight on the
pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of drugs used in many …

Aims The risk of stroke in patients with atrial fibrillation (AF) increases with age. In the
ARISTOTLE trial, apixaban when compared with warfarin reduced the rate of stroke, death …

Background The effects of anticoagulants at extremes of body weight (BW) are not well
described. The aim of this study was to analyze the pharmacokinetics/pharmacodynamics …

Abstract Aim In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced the risk of …